Zobrazeno 1 - 10
of 10
pro vyhledávání: '"Jennifer L. Driver"'
Autor:
Yun Zhu, Elizabeth C. Martin, Jennifer L. Driver, Steven Elliott, Bridgette M. Collins-Burow, Christopher W. Taylor, Lyndsay V. Rhodes, Mona Jodari-Karimi, Erik K. Flemington, Matthew E. Burow, Claire Fewell, Barbara S. Beckman, James W. Antoon
Publikováno v:
Molecular Carcinogenesis. 53:38-48
microRNAs (miRNA) are regulators of cellular pathways and alterations of normal miRNA expression levels have been shown to increase tumorigenesis. miR-24 has been demonstrated as having both tumor suppressive and oncogenic properties depending on cel
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4dedbbf80ac440fd434216d78bf26861
https://doi.org/10.1002/mc.21946
https://doi.org/10.1002/mc.21946
Autor:
Jennifer L. Driver, Steven Elliott, Evelyn M. Slaughter, James W. Antoon, Martin D. White, Hafez S. Khalili, Barbara S. Beckman, Matthew E. Burow, Charles D. Smith
Publikováno v:
Cancer Biology & Therapy. 11:678-689
Resistance to chemotherapy remains a significant obstacle in the treatment of hormone- independent breast cancer. Recent evidence suggests that altered sphingolipid signaling through increased sphingosine kinase activity may be an important mediator
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::dd2bdbba58a382f2b46b718c48aa254b
https://doi.org/10.4161/cbt.11.7.14903
https://doi.org/10.4161/cbt.11.7.14903
Publikováno v:
Experimental biology and medicine (Maywood, N.J.). 237(7)
Sphingosine kinase signaling has become of increasing interest as a cancer target in recent years. Two sphingosine kinase inhibitors, sphingosine kinase inhibitor (SKI)-II and ABC294640, are promising as potential breast cancer therapies. However, ev
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::562653eca6659d04c49f862e393f4072
https://pubmed.ncbi.nlm.nih.gov/22859737
https://pubmed.ncbi.nlm.nih.gov/22859737
Autor:
Lyndsay V. Rhodes, F. Nell Pounder, Bridgette M. Collins-Burow, Jennifer L. Driver, H. Chris Segar, Chandra R. Tate, Matthew E. Burow
Publikováno v:
Breast Cancer Research : BCR
Introduction Of the more than one million global cases of breast cancer diagnosed each year, approximately fifteen percent are characterized as triple-negative, lacking the estrogen, progesterone, and Her2/neu receptors. Lack of effective therapies,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::50281546e357def180747c9093c1f286
https://doi.org/10.1186/bcr3192
https://doi.org/10.1186/bcr3192
Autor:
Bridgette M. Collins-Burow, Steven Elliott, Meng Li, Elizabeth C. Martin, Lyndsay V. Rhodes, Ashley M. Nitschke, Matthew E. Burow, Seung Yoon Nam, Jennifer L. Driver, H. Chris Segar, Kenneth P. Nephew
Publikováno v:
Oncology Reports.
The development of drug resistance represents a major complication in the effective treatment of breast cancer. Epigenetic therapy, through the use of histone deacetylase inhibitors (HDACi) or demethylation agents, is an emerging area of therapeutic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7233ea69ba7e439cdff153ea6e3eabcf
https://doi.org/10.3892/or.2011.1488
https://doi.org/10.3892/or.2011.1488
Autor:
Matthew E. Burow, Shilong Zheng, Steven Elliott, Lyndsay V. Rhodes, Thomas E. Wiese, Florastina Payton-Stewart, Quan Jiang, Bridgette M. Collins-Burow, Cheryl L. Klein Stevens, Guangdi Wang, Qiang Zhang, Stephen M. Boue, Jennifer L. Driver, Jayalakshmi Sridhar, John A. McLachlan, Deepak Bhatnagar
Publikováno v:
Journal of medicinal chemistry. 53(16)
Daidzein (1) is a natural estrogenic isoflavone. We report here that 1 can be transformed into anti-estrogenic ligands by simple alkyl substitutions of the 7-hydroxyl hydrogen. To test the effect of such structural modifications on the hormonal activ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68ea721d14d7c8b66f856c5b2fb5adbe
https://pubmed.ncbi.nlm.nih.gov/20669983
https://pubmed.ncbi.nlm.nih.gov/20669983
Autor:
Jennifer L. Driver, M.M. Gestaut, Barbara S. Beckman, Evelyn M. Slaughter, James W. Antoon, Hafez S. Khalili, Charles D. Smith, Martin D. White, Matthew E. Burow, Steven Elliott
Publikováno v:
Cancer Research. 70:2537-2537
Resistance to chemotherapy is a major cause of breast cancer treatment failure today. The sphingolipid metabolizing enzyme sphingosine kinase converts pro-apoptotic ceramide into pro-survival sphingosine-1-phosphate (S1P). Sphingosine kinase has been
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e102b7b486f082a1f8cfb71912f0f41d
https://doi.org/10.1158/1538-7445.am10-2537
https://doi.org/10.1158/1538-7445.am10-2537
Autor:
Lee Gibbs, Lyndsay V. Rhodes, KiTani A. Parker-Johnson, Hafez S. Khalili, Matthew E. Burow, Janeque Jones, Joseph Gallien, Tamorah Hawthorne, Jennifer L. Driver, Shannon E. Muir
Publikováno v:
Cancer Research. 70:4606-4606
Patients diagnosed with triple negative breast cancer, which is the absence of the estrogen (ER), progesterone (PR), and Her2/neu receptor have a poor prognosis and there is a critical need to develop novel antineoplastic agents for this breast cance
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b2a0fdf0c9e6a42d340de3433292bd9e
https://doi.org/10.1158/1538-7445.am10-4606
https://doi.org/10.1158/1538-7445.am10-4606
Autor:
Martin, Elizabeth C., Elliott, Steven, Rhodes, Lyndsay V., Antoon, James W., Fewell, Claire, Zhu, Yun, Driver, Jennifer L., Jodari‐Karimi, Mona, Taylor, Christopher W., Flemington, Erik K., Beckman, Barbara S., Collins‐Burow, Bridgette M., Burow, Matthew E.
Publikováno v:
Molecular Carcinogenesis; Jan2014, Vol. 53 Issue 1, p38-48, 11p
Autor:
Tate, Chandra R, Rhodes, Lyndsay V, Segar, H Chris, Driver, Jennifer L, Pounder, F Nell, Burow, Matthew E, Collins-Burow, Bridgette M
Publikováno v:
Breast Cancer Research; 2012, Vol. 14 Issue 3, pR79-R79, 1p